{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:36:57Z","timestamp":1774928217172,"version":"3.50.1"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this work was to investigate the regional difference in linagliptin intestinal membrane transport and to investigate the effects of carvedilol, atorvastatin and bile salts on intestinal absorption of linagliptin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study employed an in-situ rabbit intestinal absorption technique. The membrane transport parameters of linagliptin were determined through duodenum, jejunum, ileum and colon segments. The effect of carvedilol, atorvastatin and sodium cholate was investigated by co-perfusion of each with linagliptin through jejunum and ileum.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>The study reflected incomplete linagliptin absorption from the explored intestinal segments. The resulted rank indicated that the extent of absorption decreases as we move distally through the small intestine before increasing at the ascending colon. This behaviour suggests a role of P-glycoprotein (P-gp) efflux on reduced linagliptin intestinal absorption. Co-perfusion with carvedilol, atorvastatin or bile salts significantly enhanced linagliptin absorption. This elects P-gp efflux inhibition as one possible mechanism for enhanced linagliptin intestinal membrane transport.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The study confirmed the role of P-gp efflux transporters in reduced intestinal linagliptin absorption. Co-administration of linagliptin with either carvedilol or atorvastatin can modulate the oral bioavailability of linagliptin. Bile salts can be employed as a formulation excipient for enhanced oral absorption of linagliptin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpp\/rgad006","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T16:05:33Z","timestamp":1677686733000},"page":"635-644","source":"Crossref","is-referenced-by-count":3,"title":["Investigation of the effect of concurrently administered carvedilol, atorvastatin and bile salts on intestinal absorption of linagliptin"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3349-1403","authenticated-orcid":false,"given":"Muhammad A","family":"Embaby","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, College of Pharmacy, University of Tanta , Tanta ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamal M","family":"El Maghraby","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, College of Pharmacy, University of Tanta , Tanta ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A","family":"Osman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, College of Pharmacy, University of Tanta , Tanta ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-7351","authenticated-orcid":false,"given":"Amal A","family":"Sultan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, College of Pharmacy, University of Tanta , Tanta ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"key":"2024103012211449900_CIT0001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/1574892809666140917103834","article-title":"Understanding and managing oral bioavailability: physiological concepts and patents","volume":"10","author":"Alam","year":"2015","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"2024103012211449900_CIT0002","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00003088-200140030-00002","article-title":"The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein","volume":"40","author":"Zhang","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2024103012211449900_CIT0003","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1124\/dmd.31.12.1507","article-title":"Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series)","volume":"31","author":"Pang","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"2024103012211449900_CIT0004","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pharmthera.2005.06.005","article-title":"Expression and function of efflux drug transporters in the intestine","volume":"109","author":"Takano","year":"2006","journal-title":"Pharmacol Ther"},{"key":"2024103012211449900_CIT0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1124\/jpet.107.135723","article-title":"(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors","volume":"325","author":"Thomas","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"2024103012211449900_CIT0006","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270008323753","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers","volume":"48","author":"H\u00fcttner","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"2024103012211449900_CIT0007","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.2012.04173.x","article-title":"Pharmacokinetics of linagliptin in subjects with hepatic impairment: linagliptin in hepatic impairment","volume":"74","author":"Graefe-Mody","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2024103012211449900_CIT0008","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF03261927","article-title":"Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors","volume":"51","author":"Golightly","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"2024103012211449900_CIT0009","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2165\/11536620-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects","volume":"49","author":"Retlich","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"2024103012211449900_CIT0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1124\/dmd.112.048470","article-title":"Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods","volume":"41","author":"Ishiguro","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"2024103012211449900_CIT0011","article-title":"Enhanced oral bioavailability of linagliptin by the influence of gallic acid and ellagic acid in male Wistar albino rats: involvement of p-glycoprotein inhibition","volume":"34","author":"Shaik","year":"2019","journal-title":"Drug Metab Pers Ther"},{"key":"2024103012211449900_CIT0012","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1007\/s13346-020-00839-9","article-title":"Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition","volume":"11","author":"Shah","year":"2021","journal-title":"Drug Deliv Transl Res"},{"key":"2024103012211449900_CIT0013","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/00914037.2019.1570513","article-title":"Development and evaluation of Eudragit coated environmental sensitive solid lipid nanoparticles using central composite design module for enhancement of oral bioavailability of linagliptin","volume":"69","author":"Veni","year":"2020","journal-title":"Int J Polym Mater"},{"key":"2024103012211449900_CIT0014","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ddr.21918","article-title":"Approaches to minimize the effects of P-glycoprotein in drug transport:","volume":"83","author":"Husain","year":"2022","journal-title":"Drug Dev Res"},{"key":"2024103012211449900_CIT0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm Res"},{"key":"2024103012211449900_CIT0016","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1349-7006.2003.tb01356.x","article-title":"Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil","volume":"94","author":"Kakumoto","year":"2003","journal-title":"Cancer Sci"},{"key":"2024103012211449900_CIT0017","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1592\/phco.26.11.1601","article-title":"Role of P-glycoprotein in statin drug interactions","volume":"26","author":"Holtzman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"2024103012211449900_CIT0018","year":"1996"},{"key":"2024103012211449900_CIT0019","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.colsurfb.2016.10.028","article-title":"Self dispersing mixed micelles forming systems for enhanced dissolution and intestinal permeability of hydrochlorothiazide","volume":"149","author":"Sultan","year":"2017","journal-title":"Colloids Surf B Biointerfaces"},{"key":"2024103012211449900_CIT0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/jps.2600660117","article-title":"Use of rabbits for GI drug absorption studies","volume":"66","author":"Maeda","year":"1977","journal-title":"J Pharm Sci"},{"key":"2024103012211449900_CIT0021","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/jps.2600681023","article-title":"Use of rabbits for GI drug absorption studies: relationship between dissolution rate and bioavailability of griseofulvin tablets","volume":"68","author":"Maeda","year":"1979","journal-title":"J Pharm Sci"},{"key":"2024103012211449900_CIT0022","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1248\/bpb1978.7.630","article-title":"Bioavailability of griseofulvin plain tablets in stomach-emptying controlled rabbits and the correlation with bioavailability in humans","volume":"7","author":"Aoyagi","year":"1984","journal-title":"J Pharmacobiodyn"},{"key":"2024103012211449900_CIT0023","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1023\/A:1015817426713","article-title":"Absorptive clearance of carbamazepine and selected metabolites in rabbit intestine","volume":"8","author":"Riad","year":"1991","journal-title":"Pharm Res"},{"key":"2024103012211449900_CIT0024","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/bdd.487","article-title":"Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance","volume":"27","author":"Osman","year":"2006","journal-title":"Biopharm Drug Dispos"},{"key":"2024103012211449900_CIT0025","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/jphp.12516","article-title":"Colloidal carriers for extended absorption window of furosemide","volume":"68","author":"Sultan","year":"2016","journal-title":"J Pharm Pharmacol"},{"key":"2024103012211449900_CIT0026","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0169-409X(02)00170-9","article-title":"In vitro and in vivo models for assessing drug efflux transporter activity","volume":"55","author":"Zhang","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012211449900_CIT0027","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/bdd.2047","article-title":"P-gp activity and inhibition in the different regions of human intestine ex vivo: P-gp function in human intestinal regions","volume":"38","author":"Li","year":"2017","journal-title":"Biopharm Drug Dispos"},{"key":"2024103012211449900_CIT0028","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1124\/dmd.105.007757","article-title":"Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments","volume":"34","author":"Ballent","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"2024103012211449900_CIT0029","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fphar.2015.00141","article-title":"Frog intestinal perfusion to evaluate drug permeability: application to p-gp and cyp3a4 substrates","volume":"6","author":"Yerasi","year":"2015","journal-title":"Front Pharmacol"},{"key":"2024103012211449900_CIT0030","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1023\/A:1026183200740","article-title":"P-glycoprotein increases from proximal to distal regions of human small intestine","volume":"20","author":"Mouly","year":"2003","journal-title":"Pharm Res"},{"key":"2024103012211449900_CIT0031","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1124\/dmd.108.020859","article-title":"Closing the gaps: a full scan of the intestinal expression of P-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats","volume":"36","author":"MacLean","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"2024103012211449900_CIT0032","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/jphp.13036","article-title":"Regional difference in intestinal drug absorption as a measure for the potential effect of P-glycoprotein efflux transporters","volume":"71","author":"Ashmawy","year":"2019","journal-title":"J Pharm Pharmacol"},{"key":"2024103012211449900_CIT0033","author":"(European Medicines Agency).","year":"2011"},{"key":"2024103012211449900_CIT0034","author":"(Food and Drug Administration).","year":"2011"},{"key":"2024103012211449900_CIT0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/1568026013395100","article-title":"Physicochemical profiling (solubility, permeability and charge state)","volume":"1","author":"Avdeef","year":"2001","journal-title":"Curr Top Med Chem"},{"key":"2024103012211449900_CIT0036","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2337\/diab.23.2.105","article-title":"Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study","volume":"23","author":"Garcia","year":"1974","journal-title":"Diabetes"},{"key":"2024103012211449900_CIT0037","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"2024103012211449900_CIT0038","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archinte.161.7.996","article-title":"Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study","volume":"161","author":"He","year":"2001","journal-title":"Arch Intern Med"},{"key":"2024103012211449900_CIT0039","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/hr.2017.21","article-title":"Association between changes in systolic blood pressure and incident diabetes in a community-based cohort study in Korea","volume":"40","author":"Lee","year":"2017","journal-title":"Hypertens Res"},{"key":"2024103012211449900_CIT0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1074248416644987","article-title":"Effects of carvedilol compared to nebivolol on insulin resistance and lipid profile in patients with essential hypertension","volume":"22","author":"Ozy\u0131ld\u0131z","year":"2017","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2024103012211449900_CIT0041","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0024-3205(01)01494-1","article-title":"Interaction of digoxin with antihypertensive drugs via MDR1","volume":"70","author":"Takara","year":"2002","journal-title":"Life Sci"},{"key":"2024103012211449900_CIT0042","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103012211449900_CIT0043","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/sj.bjp.0706283","article-title":"New positron emission tomography tracer [(11)C] carvedilol reveals P-glycoprotein modulation kinetics","volume":"145","author":"Bart","year":"2005","journal-title":"Br J Pharmacol"},{"key":"2024103012211449900_CIT0044","author":"(Therapeutic Goods Administration).","year":"2011"},{"issue":"3","key":"2024103012211449900_CIT0045","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3390\/pharmaceutics12030295","article-title":"Segmental-dependent solubility and permeability as key factors guiding controlled release drug product development","volume":"12","author":"Markovic","year":"2020","journal-title":"Pharmaceutics"},{"key":"2024103012211449900_CIT0046","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1345\/aph.17231","article-title":"Atorvastatin in the treatment of primary scholesterolemia and mixed dyslipidemias","volume":"32","author":"Yee","year":"1998","journal-title":"Ann Pharmacother"},{"key":"2024103012211449900_CIT0047","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"2024103012211449900_CIT0048","doi-asserted-by":"crossref","first-page":"14451","DOI":"10.3390\/molecules200814451","article-title":"Absorption-enhancing effects of bile salts","volume":"20","author":"Moghimipour","year":"2015","journal-title":"Molecules"},{"key":"2024103012211449900_CIT0049","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1001\/archinte.1972.03650040040005","article-title":"Micelle formation by bile salts: physical-chemical and thermodynamic considerations","volume":"130","author":"Carey","year":"1972","journal-title":"Arch Intern Med"},{"key":"2024103012211449900_CIT0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF03190999","article-title":"Effect of cholic acid and its keto derivatives on the analgesic action of lidocaine and associated biochemical parameters in rats","volume":"32","author":"Posa","year":"2007","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2024103012211449900_CIT0051","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ijpharm.2004.01.014","article-title":"Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers","volume":"274","author":"Ingels","year":"2004","journal-title":"Int J Pharm"},{"key":"2024103012211449900_CIT0052","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijpharm.2012.04.077","article-title":"Effect of ketocholate derivatives on methotrexate uptake in Caco-2 cell monolayers","volume":"433","author":"Chen","year":"2012","journal-title":"Int J Pharm"},{"key":"2024103012211449900_CIT0053","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-3-642-69508-7_4","article-title":"The role of the unstirred water layer in intestinal permeation.","volume-title":"Pharmacology of Intestinal Permeation II","author":"Thomson","year":"1984"},{"key":"2024103012211449900_CIT0054","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1021\/mp400179v","article-title":"Ion pairing with bile salts modulates intestinal permeability and contributes to food-drug interaction of BCS class III compound trospium chloride","volume":"10","author":"Heinen","year":"2013","journal-title":"Mol Pharm"},{"key":"2024103012211449900_CIT0055","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1021\/mp500626a","article-title":"Absorption mechanism of a physical complex of monomeric insulin and deoxycholyl-l-lysyl-methylester in the small intestine","volume":"12","author":"Mahmud","year":"2015","journal-title":"Mol Pharm"},{"key":"2024103012211449900_CIT0056","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cphy.c190007","article-title":"Intestinal absorption of bile acids in health and disease","volume":"10","author":"Ticho","year":"2019","journal-title":"Compr Physiol"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/75\/5\/635\/60217210\/rgad006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/75\/5\/635\/60217210\/rgad006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T17:16:04Z","timestamp":1730308564000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/75\/5\/635\/7059970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,1]]},"published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgad006","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,5,1]]}}}